Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · SUVEN LIFE SCIENCES LTD · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
SUVEN LIFE SCIENCES LTD
NSE: SUVEN · BSE: 530239
NSE: SUVEN · BSE: 530239
Healthcare › Healthcare › Healthcare Services › Healthcare Research Analytics & Technology
SUVEN LIFE SCIENCES LTD
StateQ1 FY27 filed
Last close · 28 Oct 2026₹268.65
Market cap₹7.1k cr
TTM P/E · P/B · EV/EBITDA— · 11.99 · —
SUVEN LIFE SCIENCES LTD is a Healthcare Services company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 12 | 14 | 12 | 7 | 7 |
| EBITDA (ex other income) | (122) | (120) | (121) | (166) | (285) |
| margin % | (1033.3) | (885.5) | (1031.0) | (2490.7) | (3998.8) |
| Owners' profit | 0 | 0 | (105) | (161) | (276) |
| EPS, as reported (₹) | (9.57) | (6.63) | (4.82) | (7.37) | (12.13) |
| ROE % · ROCE % | (126.9) · (121.8) | (31.5) · (31.2) | (38.9) · (39.0) | (146.1) · (143.9) | (46.7) · (46.5) |
| Debt / equity (x) | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | (128) | (208) | (83) | (154) | (302) |
| Capex | (20) | (3) | (2) | (37) | (5) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · SUVEN LIFE SCIENCES LTD · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 2 | 1 | 2 | 1 | 3 | 2 | 4 |
| Profit before tax | (50) | (39) | (44) | (52) | (77) | (102) | (46) | (128) |
| Net profit | (50) | (39) | (44) | (52) | (77) | (102) | (46) | (128) |
| EPS (₹) | (2.27) | (1.79) | (2.02) | (2.36) | (3.48) | (4.55) | (2.02) | (4.84) |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SYNGENE INTERNATIONAL LTD | 16,350 | 73.6 | 3.38 | 17.7 | 6.5 | 7.5 | 11.3 | 13.9 |
| INDEGENE LIMITED | 14,382 | 35.8 | 4.58 | 21.0 | 12.8 | 14.9 | — | 19.1 |
| SUVEN LIFE SCIENCES LTD ◆ | 7,092 | — | 11.99 | — | (46.7) | (46.6) | (12.0) | (3504.9) |
| VIMTA LABS LIMITED | 2,278 | 18.4 | 6.65 | 25.1 | 8.0 | 11.0 | 8.4 | 38.2 |
| BILCARE LTD. | 194 | — | 2.62 | 11.5 | (23.3) | (3.9) | 3.3 | 15.7 |
| TAKE LIMITED | 157 | 12.3 | 5.07 | 32.9 | 35.0 | 14.2 | (41.2) | 3.5 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 12.0 | 4.6 | 53 of 57 | 7% |
| ROCE | (46.6) | 8.0 | 66 of 69 | 4% |
| ROE | (46.7) | 9.1 | 55 of 57 | 4% |
| Debt / Equity | 0.0 | 0.1 | 1 of 56 | 80% |
| EBITDA margin | (3504.9) | 21.5 | 56 of 57 | 2% |
| Revenue growth | 91.0 | 20.2 | 5 of 57 | 93% |
| Profit growth | (147.7) | 11.4 | 52 of 55 | 6% |
| Market cap | 7092 | 229 | 19 of 71 | 74% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · SUVEN LIFE SCIENCES LTD · 29 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 23 Oct 2026 · Special window to re-lodge rejected physical share transfer requests | compliance | minimal | — | — |
| 7 Oct 2026 · Quarterly RTA certificate under SEBI Depositories Regulations filed | compliance | minimal | — | — |
| 28 Sept 2026 · Trading Window Closed Ahead of Q2 FY26-27 Results | compliance | minimal | — | — |
| 3 Sept 2026 · Suven Life Sciences Completes Phase-3 Patient Enrollment for Masupirdine Study | business updates | high | — | — |
| 25 Aug 2026 · 37th AGM held; all 5 resolutions passed with requisite majority | board shareholder meetings | low | — | — |
| 25 Aug 2026 · 37th AGM held on Aug 25 2026 - all 5 resolutions passed | board shareholder meetings | low | — | — |
| 11 Aug 2026 · Crisil Monitoring Agency Report for Q1 FY27 on Preferential Issue proceeds | fund raising | medium | — | — |
| 7 Aug 2026 · Suven Life Sciences publishes Q1 FY27 unaudited results in newspapers | compliance | minimal | — | — |
| 6 Aug 2026 · Suven Life Sciences Q1 FY27 results: consolidated net loss widens to about Rs 127.61 cr | results | high | — | — |
| 31 Jul 2026 · Suven Life Sciences announces 37th AGM on 25 Aug 2026, e-voting details | compliance | minimal | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in